Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer

被引：11
|
作者：
Zhu, Xiaofei [1 ]
Cao, Yangsen [1 ]
Zhang, Huojun [1 ]
机构：
[1] Second Mil Med Univ, Changhai Hosp, Dept Radiat Oncol, Shanghai 200433, Peoples R China
来源：
LANCET ONCOLOGY | 2020年 / 22卷 / 10期
关键词：
RESECTION;
D O I：
10.4143/crt.2020.928
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E424 / E424
页数：1
相关论文
共 50 条
  • [1] Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer
    Okano, Naohiro
    Mizutani, Tomonori
    Nagashima, Fumio
    Furuse, Junji
    LANCET ONCOLOGY, 2021, 22 (10): : E423 - E423
  • [2] Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
    Zhu, Xiaofei
    Cao, Yangsen
    Liu, Wenyu
    Ju, Xiaoping
    Zhao, Xianzhi
    Jiang, Lingong
    Ye, Yusheng
    Jin, Gang
    Zhang, Huojun
    LANCET ONCOLOGY, 2022, 23 (03): : E105 - E115
  • [3] RETRACTED: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial (Retracted Article)
    Zhu, Xiaofei
    Cao, Yangsen
    Liu, Wenyu
    Ju, Xiaoping
    Zhao, Xianzhi
    Jiang, Lingong
    Ye, Yusheng
    Jin, Gang
    Zhang, Huojun
    LANCET ONCOLOGY, 2021, 22 (08): : 1093 - 1102
  • [4] RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial (Retraction of Vol 22, Pg 1093, 2021)
    Zhu, X.
    Cao, Y.
    Liu, W.
    LANCET ONCOLOGY, 2022, 23 (03): : 330 - 330
  • [5] Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial
    Zhu, Xiaofei
    Liu, Wenyu
    Cao, Yangsen
    Ju, Xiaoping
    Zhao, Xianzhi
    Jiang, Lingong
    Ye, Yusheng
    Zhang, Huojun
    ECLINICALMEDICINE, 2023, 55
  • [6] Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer
    Trakul, Nicholas
    Koong, Albert C.
    Chang, Daniel T.
    SEMINARS IN RADIATION ONCOLOGY, 2014, 24 (02) : 140 - 147
  • [7] Advances of stereotactic body radiotherapy in pancreatic cancer
    Wei, Qichun
    Yu, Wei
    Rosati, Lauren M.
    Herman, Joseph M.
    CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (04) : 349 - 357
  • [8] Advances of stereotactic body radiotherapy in pancreatic cancer
    Qichun Wei
    Wei Yu
    Lauren M.Rosati
    Joseph M.Herman
    ChineseJournalofCancerResearch, 2015, 27 (04) : 349 - 357
  • [9] Stereotactic body radiotherapy for unresectable pancreatic cancer
    Chang, Stephanie T.
    Goodman, Karyn A.
    Yang, George R.
    Koong, Albert C.
    IMRT, IGRT, SBRT: ADVANCES IN THE TREATMENT PLANNING AND DELIVERY OF RADIOTHERAPY, 2007, 40 : 386 - 394
  • [10] Stereotactic Body Radiotherapy as an Effective Treatment for Pancreatic Cancer
    Hurmuz, Pervin
    Cengiz, Mustafa
    Ozyigit, Gokhan
    Sari, Sezin Yuce
    Kahvecioglu, Alper
    Esen, Selenge Beduk
    Yalcin, Suayib
    Zorlu, Faruk
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
12345